2009 American Society of Clinical Oncology (ASCO) Annual Meeting

The following information is intended to summarize a selection of the pancreatic cancer sessions at the 2009 ASCO Annual Meeting held May 29-June 2, 2009 in Orlando, Florida.Click on the links below to download a detailed summary (pdf format) of the pancreatic cancer sessions of interest.

Clinical Science Symposium

Education Session

GI Poster Display/Discussion Session

GI Noncolorectal Oral Abstract Session

3/17/09

Obesity Increases Risk of Node-Positive Pancreatic Cancer

3/12/09

Pfizer's Phase III Sutent Trial Stopped Early; Drug Shows Definite Benefit in Pancreatic Islet Cell Cancer

3/10/09

Study Links Blood Type and Pancreatic Cancer - Sheds Light on Disease Biology

3/3/09

Alcohol Consumption Linked to Pancreatic Cancer Risk

3/2/09

University of Michigan Researchers Identify a Gene Overexpressed in Pancreatic Cancer

2/26/09

One in Three Common Cancers May Be Preventable

2009 Gastrointestinal Cancers Symposium

The following information is intended to summarize a selection of the pancreatic cancer sessions at the January 2009 GI Cancers Symposium held in San Francisco, California.　Click on the links below to download a summary (pdf format) of the pancreatic cancer sessions of interest:

Oral Abstract Presentations

Phase II trial of Endo-TAG-1 in combination with gemcitabine in patients with unresectable pancreatic cancer

Effects of DNA mismatch repair gene polymorphisms on clinical outcome of pancreatic cancer

Phase II trial of daily oral RAD001 in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy

General Session Presentation

Rash as a marker for the efficacy of gemcitabine plus erlotinib-based therapy in pancreatic cancer: from the AVITA study

2/13/09

New Research Offers Hope for Finding Pancreatic Cancer Early in High-Risk Patients

1/30/09

Pfizer Discontinues Late-Phase Pancreatic Cancer Trial

1/20/09

EndoTAG-1 Shows Promise in Advanced Pancreatic Cancer

Rexin-G Shrinks Metastatic Tumors in Chemotherapy-Resistant Pancreatic Cancer: Analysis of a U.S. Phase I/II Clinical Trial

RAD001 Benefits Patients with Metastatic Pancreatic Neuroendocrine Tumors

1/15/09

DNA Repair Patterns May Predict Risk of Pancreatic Cancer

1/8/09

Artificial Fever Studied to Kill Pancreatic Cancer Cells

1/7/09

Pancreatic Cancer Patients Find Hope In Experimental Treatment

 -------------------------------------------------------------------------